Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks (IPOP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is compare the effects of consuming glucose- and fructose-sweetened beverages on appetite, body weight, body fat, and the amount of energy the body burns as well as effects on blood pressure, hormones, blood triglycerides and cholesterol, and the body's sensitivity to the insulin.
| Condition | Intervention |
|---|---|
|
Metabolic Syndrome Insulin Resistance Dyslipidemia |
Other: Glucose Other: Fructose |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science |
| Official Title: | Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks on Hormones and Lipids |
- 24-hour triglyceride area under the curve [ Time Frame: Baseline and 8-week intervention ] [ Designated as safety issue: No ]32 serial blood samples are collected over a 24 hour period.
- Insulin sensitivity index [ Time Frame: Baseline and 8-week intervention ] [ Designated as safety issue: No ]Insulin sensitivity is assessed using the deuterated glucose disposal method.
| Enrollment: | 32 |
| Study Start Date: | July 2005 |
| Estimated Study Completion Date: | July 2012 |
| Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Glucose |
Other: Glucose
25% dose at 8-week intervention assigned to subjects.
Other Name: sugar
|
| Fructose |
Other: Fructose
25% dose at 8-week intervention assigned to subjects.
Other Name: sugar
|
Detailed Description:
The study is designed as a prospective, blinded diet intervention study during which the participants consume either fructose- or glucose-sweetened beverages (25% of energy) with meals. Experimental procedures, including 24-hour serial blood sampling, 26-h stable isotoped infusions, post-heparin blood collection, gluteal biopsies, metabolic rate monitoring, computed tomography scans of the abdomen, and Oral Glucose Tolerance and Disposal Tests, are performed during baseline and at the end of a 10-week intervention period at the UC Davis School of Medicine/Sacramento Veterans Affairs Medical Center Clinical Research Center (CCRC). During the 2-week inpatient baseline period, subjects are served energy balanced diets containing 15% of energy as protein, 30% as fat, and 55% as complex carbohydrate. Following the baseline period, the subjects reside at home for 8 weeks and consume their usual ad libitum diet along with 25% of energy requirements as fructose- or glucose-sweetened beverages. Subjects then return to the CCRC for the 2-week inpatient intervention period at the end of the study and are served energy-balanced diets containing 15% of energy as protein, 30% as fat, 30% as complex carbohydrate and 25% of energy as fructose- or glucose-sweetened beverage.
Eligibility| Ages Eligible for Study: | 40 Years to 72 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Self-report of stable body weight
- Women were post-menopausal based on a self-report of no menstruation for at least one year
Exclusion Criteria:
- evidence of diabetes
- renal or hepatic disease
- fasting serum TG concentrations >400 mg/dl
- hypertension (>140/90 mg Hg)
- surgery for weight loss
- individuals who smoked
- reported exercise of more than 3.5 hours/week at a level more vigorous than walking
- having used thyroid, lipid-lowering, glucose-lowering, anti-hypertensive, anti-depressant, or weight loss medications
- habitual ingestion of more than one sugar-sweetened beverage/day or more than two alcoholic beverages/day
Contacts and Locations| United States, California | |
| Clinical Research Center | |
| Sacramento, California, United States, 95655 | |
| Principal Investigator: | Peter J Havel, D.V.M. | University of California, Davis |
| Study Director: | Kimber L Stanhope, Ph.D, R.D. | University of California, Davis |
More Information
No publications provided by University of California, Davis
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Kimber Stanhope, Associate Project Scientist, University of California, Davis |
| ClinicalTrials.gov Identifier: | NCT01165853 History of Changes |
| Other Study ID Numbers: | 200412368, R01HL075675 |
| Study First Received: | July 16, 2010 |
| Last Updated: | March 12, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Insulin Resistance Dyslipidemias Metabolic Syndrome X Hyperinsulinism |
Glucose Metabolism Disorders Metabolic Diseases Lipid Metabolism Disorders |
ClinicalTrials.gov processed this record on May 16, 2013